ATRC Key Statistics, Chart & Performance
The current stock price of ATRC is 41.46 USD. In the past month the price increased by 0.68%. In the past year, price increased by 32%.
ATRC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.23 | 218.96B | ||
| ISRG | INTUITIVE SURGICAL INC | 68.09 | 207.82B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.1 | 144.75B | ||
| SYK | STRYKER CORP | 27.91 | 140.55B | ||
| BDX | BECTON DICKINSON AND CO | 14.06 | 57.87B | ||
| IDXX | IDEXX LABORATORIES INC | 56.57 | 56.96B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.12 | 49.40B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 19.02 | 39.76B | ||
| RMD | RESMED INC | 25.5 | 36.85B | ||
| DXCM | DEXCOM INC | 36.24 | 26.29B | ||
| PODD | INSULET CORP | 63.25 | 20.33B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.48 | 18.40B |
Related stock screener links
About ATRC
Company Profile
AtriCure, Inc. engages in the development, manufacture, and sale of surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. The company is headquartered in Mason, Ohio and currently employs 1,300 full-time employees. The company went IPO on 2005-08-05. The firm's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The firm's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.
Company Info
ATRICURE INC
7555 Innovation Way
Mason OHIO 45040 US
CEO: Michael H. Carrel
Employees: 1300
Phone: 15137554100
ATRICURE INC / ATRC FAQ
What does ATRC do?
AtriCure, Inc. engages in the development, manufacture, and sale of surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. The company is headquartered in Mason, Ohio and currently employs 1,300 full-time employees. The company went IPO on 2005-08-05. The firm's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The firm's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.
What is the current price of ATRC stock?
The current stock price of ATRC is 41.46 USD. The price decreased by -2.23% in the last trading session.
Does ATRC stock pay dividends?
ATRC does not pay a dividend.
How is the ChartMill rating for ATRICURE INC?
ATRC has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What sector and industry does ATRICURE INC belong to?
ATRICURE INC (ATRC) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
What is the employee count for ATRC stock?
ATRICURE INC (ATRC) currently has 1300 employees.
Who owns ATRICURE INC?
You can find the ownership structure of ATRICURE INC (ATRC) on the Ownership tab.
ATRC Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ATRC. When comparing the yearly performance of all stocks, ATRC is one of the better performing stocks in the market, outperforming 82.29% of all stocks.
ATRC Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ATRC. No worries on liquidiy or solvency for ATRC as it has an excellent financial health rating, but there are worries on the profitability.
ATRC Financial Highlights
Over the last trailing twelve months ATRC reported a non-GAAP Earnings per Share(EPS) of -0.25. The EPS increased by 69.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -4.6% | ||
| ROE | -6.13% | ||
| Debt/Equity | 0.14 |
ATRC Forecast & Estimates
15 analysts have analysed ATRC and the average price target is 53.38 USD. This implies a price increase of 28.75% is expected in the next year compared to the current price of 41.46.
For the next year, analysts expect an EPS growth of 46.71% and a revenue growth 15.08% for ATRC